消化管癌に対する外科治療選択のPlatform

出版社： メジカルビュー社
著者：
発行日： 2019-12-25
分野： 臨床医学：外科  >  消化器外科学
ISBN： 9784758315388
電子書籍版： 2019-12-25 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

8,250 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

8,250 円(税込)

購入する

商品紹介

消化管癌の外科治療に関連するガイドラインの作成に影響を与えた論文のうち，特にエビデンスレベルの高い論文（Key論文）について「研究背景」「研究目的」「対象」「結論」などの要点を簡潔にまとめ，難しい内容を丁寧に説明。項目の始めと終わりに内容に対するQuestionを載せ，読者の臨床判断力や知識を自己評価できる構成となっている。さらに，それぞれのKey論文がガイドラインやその他の論文に与えた影響や，読んでおきたい関連論文なども紹介することで，周辺知識も身に付けられるので，消化器外科専門医試験の筆記試験にも役立つ内容となっている。

目次

  • 食道癌
    　内視鏡治療
    　　1. 食道表在癌（T1）に対する治療方針
    　三領域リンパ節郭清
    　　2. 食道癌根治術における頸部リンパ節郭清の意義
    　周術期化学療法
    　　3. 食道癌に対する周術期化学療法
    　食道胃接合部癌に対する手術
    　　4. 食道胃接合部癌に対するリンパ節郭清：組織型と郭清範囲
    　　5. 食道胃接合部癌に対する至適リンパ節郭清と胃切除の範囲

    胃癌
    　内視鏡治療
    　　1. 早期胃癌に対する内視鏡治療の適応
    　早期癌に対する手術
    　　2. 胃上部早期癌に対する手術
    　　3. 早期胃癌に対する幽門保存胃切除術（PPG）の適応
    　進行癌に対するリンパ節郭清
    　　4. 進行胃癌に対する至適リンパ節郭清
    　　5. 胃上部進行癌に対する拡大リンパ節郭清：脾摘の意義
    　　6. 進行胃癌に対する拡大リンパ節郭清：予防的大動脈周囲リンパ節郭清の意義
    　食道胃接合部癌へのアプローチ
    　　7. 食道胃接合部癌に対する外科的アプローチ
    　腹腔鏡下手術
    　　8. 早期癌に対する腹腔鏡下幽門側胃切除術の評価
    　　9. 進行癌に対する腹腔鏡下幽門側胃切除術の評価
    　根治手術不能な胃癌に対する手術
    　　10. 非治癒切除因子を有する胃癌に対する癌の減量手術
    　周術期化学療法
    　　11. 胃癌に対する術後補助化学療法

    大腸癌
    　大腸癌に対する内視鏡治療
    　　1. 大腸癌に対する内視鏡治療後の追加切除
    　結腸癌に対するリンパ節郭清
    　　2. 結腸癌に対する全結腸間膜切除（CME）の意義
    　　3. 結腸癌に対する手術術式：日本のD3 リンパ節郭清と欧州のCME ＋ CVL の比較
    　結腸癌に対する腹腔鏡下手術
    　　4. 結腸癌に対する腹腔鏡下手術の有用性
    　結腸癌に対する術後補助化学療法
    　　5. 結腸癌に対する術後補助化学療法（１）
    　　6. 結腸癌に対する術後補助化学療法（２）
    　直腸癌に対する肛門側切離断端長
    　　7. 直腸癌手術における肛門側切離マージン
    　直腸癌に対するリンパ節郭清
    　　8. 直腸癌に対するtotal mesorectal excision（TME）
    　　9. 直腸癌に対する側方リンパ節郭清の意義
    　直腸癌に対する腹腔鏡下手術
    　　10. 直腸癌に対する腹腔鏡下手術の有用性
    　直腸癌に対する周術期化学放射線療法
    　　11. 局所進行直腸癌に対する術前化学放射線療法
    　根治手術不能な大腸癌に対する手術
    　　12. 遠隔転移を有する大腸癌に対する原発腫瘍切除の意義

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

食道癌

P.4 掲載の参考文献
Tanaka T, Matono S, Mori N, Shirouzu K, Fujita H. T1 squamous cell carcinoma of the esophagus:long-term outcomes and prognostic factors after esophagectomy. Ann Surg Oncol 2014;21:932-8.
PubMed
P.8 掲載の参考文献
1) Akutu Y, et al:The overall prevalence of metastasis in T1 esophageal squamous cell carcinoma. Ann Surg 2013;257:1032-8.
 
2) Yamashina T, et al:Long term outcome and metastatic risk after endoscopic resection of surperficial esophageal squamous cell carcinoma. Am J Gastroenterol 2013;108:544-51.
 
3) Eguchi T, et al:Histological criteria for additional treatment after endoscopic mucosal resection for esophageal cancer:analysis of 464 surgically resected cases. Modern Patho 2006;19:475-80.
 
P.12 掲載の参考文献
Nishihira T, Hirayama K, Mori S. A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. Am J Surg 1998;175:47-51.
 
P.17 掲載の参考文献
1) Kato H, et al:Evaluation of neck lymph node dissection for thoracic esophageal carcinoma. Ann Thorac Surg 1991;51:931-5.
PubMed
2) Fujita H, et al:Optimal lymphadenectomy for squamous cell carcinoma in the thoracic esophagus:comparing the short and long-term outcome. World J Surg 2003;27:571-9.
 
3) Igaki H, et al:Improved survival for patients with upper and/or middle mediastinal lymph node metastasis of squamous cell carcinoma of the lower thoracic esophagus treated with 3-field dissection. Ann Surg 2004;239:483-90.
 
4) Tachimori Y, et al:The Registration Committee for Esophageal Cancer of the Japan Esophageal Society:Efficacy of lymph node dissection for each station based on esophageal tumor location. Esophagus 2016;13:138-45.
 
5) Udagawa H, et al:The importance of grouping of lymph node stations and rationale of three-field lymphoadenoetomy for thoracic esophageal cancer. J Surg Oncol 2012;106:742-7.
PubMed
6) Fang WT, et al:Selective three-field lymphadenectomy for thoracic esophageal squamous carcinoma. Dis Esophagus 2007;20:206-11.
PubMed
7) Noguchi T, et al:Two-step three-field lymph node dissection is beneficial for thoracic esophageal carcinoma. Dis Esophagus 2004;17:27-31.
PubMed
P.22 掲載の参考文献
Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, Ikeda K, Kanda T, Tsujinaka T, Nakamura K, Fukuda H. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 2012;19:68-74.
 
P.29 掲載の参考文献
1) Shapiro J, et al:Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS):long-term results of a randomised controlled trial. Lancet Oncol 2015;16:1090-8.
 
2) Klevebro F, et al:Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction:A randomized clinical trial of neoadjuvent chemotherapy vs. neoadjuvant chemoradiation. Eur J Surg Oncol 2015;41:920-6.
PubMed
P.33 掲載の参考文献
Yoshikawa T, Takeuchi H, Hasegawa S, Nozaki I, Kishi K, Ito S, Ohi M, Mine S, Hara J, Matsuda T, Hiki N, Kurokawa Y. Theoretical therapeutic impact of lymph node dissection on adenocarcinoma and squamous cell carcinoma of the esophagogastric junction. Gastric Cancer 2016;19:143-9.
 
P.38 掲載の参考文献
1) Sasako M, et al:Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia:a randomised controlled trial. Lancet Oncol 2006;7:644-51.
PubMed
2) Hosokawa Y, et al:Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification:experience at a single institution in Japan. Ann Surg Oncol 2012:19:677-83.
 
P.42 掲載の参考文献
Yamashita H, Seto Y, Sano T, Makuuchi H, Ando N, Sasako M;Japanese Gastric Cancer Association and the Japan Esophageal Society. Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma. Gastric Cancer 2017;20:69-83.
 
P.53 掲載の参考文献
1) Sasako M, et al:Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia:a randomised controlled trial. Lancet Oncol 2006;7:644-51.
PubMed
2) Sano T, et al:Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma. Ann Surg 2017;265:277-83.
PubMed

胃癌

P.58 掲載の参考文献
Hasuike N, Ono H, Boku N, Mizusawa J, Takizawa K, Fukuda H, Oda I, Doyama H, Kaneko K, Hori S, Iishi H, Kurokawa Y, Muto M;Gastrointestinal Endoscopy Group of Japan Clinical Oncology Group (JCOG-GIESG). A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a):the Japan Clinical:Oncology Group study (JCOG0607). Gastric Cancer 2018;21:114-23.
 
P.64 掲載の参考文献
1) Kurokawa Y, et al:A phase II trial of endoscopic submucosal dissection for mucosal gastric cancer:Japan clinical oncology group study JCOG0607. Jpn J Clin Oncol 2009;39:464-6.
 
2) Takizawa K, et al:A phase II trial of endoscopic submucosal dissection for early gastric cancer of undifferentiated type:Japan clinical oncology group study JCOG1009/1010. Jpn J Clin Oncol 2013;43:87-91.
 
P.69 掲載の参考文献
Rosa F, Quero G, Fiorillo C, Bissolati M, Cipollari C, Rausei S, Chiari D, Ruspi L, de Manzoni G, Costamagna G, Doglietto GB, Alfieri S. Total vs proximal gastrectomy for adenocarcinoma of the upper third of the stomach:a propensity-score-matched analysis of a multicenter western experience (On behalf of the Italian Research Group for Gastric Cancer-GIRCG). Gastric Cancer 2018;21:845-52.
 
P.75 掲載の参考文献
1) Jung DH, et al:Proximal Gastrectomy for Gastric Cancer. J Gastric Cancer 2015;15:77-86.
 
2) Ichikawa D, et al:Long-term outcomes of patients who underwent limited proximal gastrectomy. Gastric Cancer 2014;17:141-5.
PubMed
3) Takiguchi N, et al:Long-term quality-of-life comparison of total gastrectomy and proximal gastrectomy by postgastrectomy syndrome assessment scale (PGSAS-45):a nationwide multi-institutional study. Gastric Cancer. 2015;18:407-16.
PubMed
4) Nomura E, et al:Functional evaluation comparing the double-tract method and the jejunal interposition method following laparoscopic proximal gastrectomy for gastric cancer:an investigation including laparoscopic total gastrectomy. Surg Today 2018;49:38-48.
PubMed
5) Ueda Y, et al:Laparoscopic proximal gastrectomy for early gastric cancer. Surg Today 2017;47:538-47.
PubMed
P.80 掲載の参考文献
Aizawa M, Honda M, Hiki N, Kinoshita T, Yabusaki H, Nunobe S, Shibasaki H, Matsuki A, Watanabe M, Abe T. Oncological outcomes of function-preserving gastrectomy for early gastric cancer:a multicenter propensity score matched cohort analysis comparing pylorus-preserving gastrectomy versus conventional distal gastrectomy. Gastric Cancer 2017;20:709-17.
PubMed
P.86 掲載の参考文献
1) Tsujiura M, et al:Excellent long-term prognosis and favorable postoperative nutritional status after laparoscopic pylorus-preserving gastrectomy. Ann Surg Oncol 2007;24:2233-40.
 
2) Fujita J, et al:Assessment of postoperative quality of life following pyloruspreserving gastrectomy and Billroth-I distal gastrectomy in gastric cancer patients:results of the nationwide postgastrectomy syndrome assessment study. Gastric Cancer 2016;19:302-11.
 
P.92 掲載の参考文献
Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, Meyer S, Plukker JT, Van Elk P, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H;Dutch Gastric Cancer Group. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999;340:908-14.
PubMed
P.98 掲載の参考文献
1) Songun I, et al:Surgical treatment of gastric cancer:15-year follow-up results of the randomized nationwide Dutch D1D2 trial. Lancet Oncol 2010;11:439-49.
PubMed
2) Watanabe M, et al:Clinical significance of splenic hilar dissection with splenectomy in advanced proximal gastric cancer:An analysis at a single institution in Japan. World J Surg 2016;40:1165-71.
 
P.103 掲載の参考文献
Sano T, Sasako M, Mizusawa J, Yamamoto S, Katai H, Yoshikawa T, Nashimoto A, Ito S, Kaji M, Imamura H, Fukushima N, Fujitani K;Stomach Cancer Study Group of the Japan Clinical Oncology Group. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma. Ann Surg 2017;265:277-83.
 
P.108 掲載の参考文献
1) Watanabe M, et al:Clinical significance of splenic hilar dissection with splenectomy in advanced proximal gastric cancer:An analysis at a single institution in Japan. World J Surg 2016;40:1165-71.
 
P.112 掲載の参考文献
Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K;Japan Clinical Oncology Group. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008;359:453-62.
PubMed
P.117 掲載の参考文献
1) Sano T, et al:Gastric cancer surgery:morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended paraaortic lymphadenectomy-Japan Clinical Oncology Group Study 9501. J Clin Oncol 2004;22:2767-73.
 
2) Tsuburaya A, et al:Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg 2014;101:653-60.
 
P.121 掲載の参考文献
Sasako M, Sano T, Yamamoto S, Sairenji M, Arai K, Kinoshita T, Nashimoto A, Hiratsuka M;Japan Clinical Oncology Group (JCOG). Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia:a randomized controlled trial. Lancet Oncol 2006;7:644-51.
PubMed
P.127 掲載の参考文献
1) Kurokawa Y, et al:Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the oesophagogastric junction or gastric cardia. Br J Surg 2015;102:341-8.
PubMed
2) Kurokawa Y, et al:Institutional variation in short- and long-term outcomes after surgery for gastric or esophagogastric junction adenocarcinoma:correlative study of two randomized phase III trial (JCOG 9501 and JCOG 9502). Gastric Cancer 2017;20:508-16.
 
P.131 掲載の参考文献
Hiki N, Katai H, Mizusawa J, Nakamura K, Nakamori M, Yoshikawa T, Kojima K, Imamoto H, Ninomiya M, Kitano S, Terashima M;Stomach Cancer Study Group of Japan Clinical Oncology Group. Long-term outcomes of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer:a multicenter phase II trial (JCOG0703). Gastric Cancer 2018;21:155-61.
 
P.137 掲載の参考文献
1) Katai H, et al:Short-term surgical outcomes from a phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer. Japan Clinical Oncology Group Study JCOG0912. Gastric Cancer 2017;20:699-708.
 
2) Kim W, et al:Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage I gastric cancer:Short-term outcomes from a multicenter randomized controlled trial (KLASS-01). Ann Surg 2016;263:28-35.
 
3) Hur H, et al:Efficacy of laparoscopic subtotal gastrectomy with D2 lymphadenectomy for locally advanced gastric cancer:the protocol of KLASS-02 multicenter randomized controlled clinical trial. BMC Cancer 2015;15:355.
PubMed
4) Katai H, et al:Safety and feasibility of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer:A multicenter phase II trial (JCOG 0703). Gastric cancer 2010;13:238-44.
 
P.142 掲載の参考文献
Park YK, Yoon HM, Kim YW, Park JY, Ryu KW, Lee YJ, Jeong O, Yoon KY, Lee JH, Lee SE, Yu W, Jeong SH, Kim T, Kim S, Nam BH;COACT group. Laparoscopy-assisted versus open D2 distal gastrectomy for advanced gastric cancer:results from a randomized phase II multicenter clinical trial (COACT1001). Ann Surg 2018;267:638-45.
 
P.149 掲載の参考文献
1) Lee HJ, et al:Short-term outcomes of multicenter randomized controlled trial comparing laparoscopic distal gastrectomy with D2 lymphadenectomy to open distal gastrectomy for locally advanced gastric cancer (KLASS-02-RCT). Ann Surg 2019;Feb 9. [Epub ahead of print]
 
2) Li Z, et al:Surgical and long-term oncologic outcomes of laparoscopic and open gastrectomy for serosa-positive (pT4a) gastric cancer:A propensity scorematched analysis. Surg Oncol 2019;28:167-73.
PubMed
3) Huang X, et al:Laparoscopic-assisted versus open D2 gastrectomy for advanced gastric cancer in highly selective patients:Short-term surgical and chemotherapy outcomes of a prospective cohort study. Am J Clin Oncol 2019;42:459-65.
PubMed
4) Kim SH, et al:Oncologic outcomes after laparoscopic and open distal gastrectomy for advanced gastric cancer:Propensity score matching analysis. J Gastric Cancer 2019;19:83-91.
 
5) Ahn SH, et al:Long-term survival outcomes of laparoscopic gastrectomy for advanced gastric cancer:Five-year results of a Phase II prospective clinical trial. J Gastric Cancer 2019;19:102-10.
 
6) Hiki N, et al:Higher incidence of pancreatic fistula in laparoscopic gastrectomy. Real-world evidence from a nationwide prospective cohort study. Gastric Cancer 2018;21:162-70.
PubMed
P.154 掲載の参考文献
Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, Iwasaki Y, Hyung WJ, Takagane A, Park DJ, Yoshikawa T, Hahn S, Nakamura K, Park CH, Kurokawa Y, Bang YJ, Park BJ, Sasako M, Tsujinaka T;REGATTA study investigators. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA):a phase 3, randomised controlled trial. Lancet Oncol 2016;17:309-18.
 
P.160 掲載の参考文献
1) Yoshida K, et al:Is conversion therapy possible in stage IV gastric cancer:the proposal of new biological categories of classification. Gastric Cancer 2016;19:329-38.
 
2) Oki E, et al:Surgical treatment of liver metastasis of gastric cancer:a retrospective multicenter cohort study (KSCC1302). Gastric Cancer 2016;19:968-76.
 
3) Kodera Y, et al:Long-term follow up of patients who were positive for peritoneal lavage cytology:final report from the CCOG0301 study. Gastric Cancer 2012;15:335-7.
PubMed
P.164 掲載の参考文献
Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K, for the ACTSGC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1863-5.
 
P.169 掲載の参考文献
1) Sasako M, et al:Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011;29:4387-93.
PubMed
2) Takahari D, et al:Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer. Cancer Chemother Pharmacol 2011;67:1423-8.
 

大腸癌

P.175 掲載の参考文献
Ueno H, Mochizuki H, Hashiguchi Y, Shimazaki H, Aida S, Hase K, Matsukuma S, Kanai T, Kurihara H, Ozawa K, Yoshimura K, Bekku S. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 2004;127:385-94.
PubMed
P.181 掲載の参考文献
1) Ikematsu H, et al:Long-term outcomes after resection for submucosal invasive colorectal cancers. Gastroentelorogy 2013;144:551-9.
 
2) Matsuda T, et al:Risk of lymph node metastasis in patients with pedunculated type early invasive colorectal cancer:A retrospective multicenter study. Cancer Sci 2011;102:1693-7.
PubMed
3) Oka S, et al:Mid-term prognosis after endoscopic resection for submucosal colorectal carcinoma:summary of a multicenter questionnaire survey conducted by the colorectal endoscopic resection standardization implementation working group in Japanese Society for Cancer of the Colon and Rectum. Dig Endosc 2011;23:190-4.
 
P.187 掲載の参考文献
Bertelsen CA, Neuenschwander AU, Jansen JE, Wilhelmsen M, Kirkegaard-Klitbo A, Tenma JR, Bols B, Ingeholm P, Rasmussen LA, Jepsen LV, Iversen ER, Kristensen B, Gogenur I;Danish Colorectal Cancer Group. Disease-free survival after complete mesocolic excision compared with conventional colon cancer surgery:a retrospective, population-based study. Lancet Oncol 2015;16:161-8.
PubMed
P.193 掲載の参考文献
1) Hohenberger W, et al:Standardized surgery for colonic cancer:complete mesocolic excision and central ligation--technical notes and outcome. Colorectal Dis 2009;11:354-64.
PubMed
2) Bokey EL, et al:Surgical technique and survival in patients having a curative resection for colon cancer. Dis Colon Rectum 2003;46:860-6.
PubMed
P.199 掲載の参考文献
West NP, Kobayashi H, Takahashi K, Perrakis A, Weber K, Hohenberger W, Sugihara K, Quirke P. Understanding optimal colonic cancer surgery:comparison of Japanese D3 resection and European complete mesocolic excision with central vascular ligation. J Clin Oncol 2012;30:1763-9.
PubMed
P.205 掲載の参考文献
1) Hida J, et al:The extent of lymph node dissection for colon carcinoma:the potential impact on laparoscopic surgery. Cancer 1997;80:188-92.
PubMed
2) Gao Z, et al:Efficacy and safety of complete mesocolic excision in patients with colon cancer:Three-year results from a prospective, nonrandomized, double-blind, controlled trial. Ann Surg 2018 Aug 24. doi:10.1097/SLA.0000000000003012. [Epub ahead of print]
 
P.210 掲載の参考文献
Kitano S, Inomata M, Mizusawa J, Katayama H, Watanabe M, Yamamoto S, Ito M, Saito S, Fujii S, Konishi F, Saida Y, Hasegawa H, Akagi T, Sugihara K, Yamaguchi T, Masaki T, Fukunaga Y, Murata K, Okajima M, Moriya Y, Shimada Y. Survival outcomes following laparoscopic versus open D3 dissection for stage II or III colon cancer (JCOG0404):a phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol 2017;2:261-8.
PubMed
P.216 掲載の参考文献
1) Weeks JC, et al:Short-term quality-of-life outcomes following laparoscopicassisted colectomy vs open colectomy for colon cancer:a randomized trial. JAMA 2002;287:321-8.
PubMed
2) Veldkamp R, et al:Laparoscopic surgery versus open surgery for colon cancer:short-term outcomes of a randomised trial. Lancet Oncol 2005;6:477-84.
PubMed
3) Guillou PJ, et al:Short-term endpoints of conventional versus laparoscopicassisted surgery in patients with colorectal cancer (MRC CLASICC trial):multicentre, randomised controlled trial. Lancet 2005;365:1718-26.
PubMed
P.220 掲載の参考文献
Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A;Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.
 
P.226 掲載の参考文献
1) Andre T, et al:Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-16.
 
2) Tournigand C, et al:Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer;Subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant treatment of colon cancer trial. J Clin Oncol 2012;30:3353-60.
 
3) Andre T, et al:Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer;Update 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol 2015;33:4176-87.
PubMed
P.230 掲載の参考文献
Tournigand C, Andre T, Bonnetain F, Chibaudel B, Lledo G, Hickish T, Tabernero J, Boni C, Bachet JB, Teixeira L, de Gramont A. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer:Subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant treatment of colon cancer trial. J Clin Oncol 2012;30:3353-60.
 
P.235 掲載の参考文献
1) Andre T, et al:Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.
PubMed
2) Andre T, et al:Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-16.
 
3) Andre T, et al:Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer;Update 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol 2015;33:4176-87.
PubMed
P.239 掲載の参考文献
Ono C, Yoshinaga K, Enomoto M, Sugihara K. Discontinuous rectal cancer spread in the mesorectum and the optimal distal clearance margin in situ. Dis Colon Rectum 2002;45:744-9.
PubMed
P.244 掲載の参考文献
1) Vernava AM 3rd, et al:A prospective evaluation of distal margins in carcinoma of the rectum. Surg Gynecol Obstet 1992;175:333-6.
PubMed
2) Moore HG, et al:Adequacy of 1cm distal margin after restorative rectal cancer resection with sharp mesorectal excision and preoperative combined-modality therapy. Ann Surg Oncol 2003;10:80-5.
PubMed
3) Rullier E, et al:Sphincter-saving resection for all rectal carcinomas:the end of the 2-cm distal rule. Ann Surg 2005;241:465-9.
 
P.248 掲載の参考文献
Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery-the clue to pelvic recurrence? Br J Surg 1982;69:613-6.
PubMed
P.253 掲載の参考文献
1) Enker WE, et al:Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 1995;181:335-46.
PubMed
2) Peeters KC, et al:The TME trial after a median follow-up of 6 years:increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007;246:693-701.
PubMed
3) Kapiteijn E, et al:Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-46.
PubMed
4) Lowry AC, et al:Consensus statement of definitions for anorectal physiology and rectal cancer. Dis Colon Rectum 2001;44:915-9.
PubMed
P.257 掲載の参考文献
Fujita S, Mizusawa J, Kanemitsu Y, Ito M, Kinugasa Y, Komori K, Ohue M, Ota M, Akazai Y, Shiozawa M, Yamaguchi T, Bandou H, Katsumata K, Murata K, Akagi Y, Takiguchi N, Saida Y, Nakamura K, Fukuda H, Akasu T, Moriya Y;Colorectal Cancer Study Group of Japan Clinical Oncology Group. Mesorectal excision with or without lateral lymph node dissection for clinical stage II/III lower rectal cancer (JCOG0212):A multicenter, randomized controlled, noninferiority trial. Ann Surg 2017;266:201-7.
 
P.262 掲載の参考文献
1) Broholm M, et al:Possible benefits of robot-assisted rectal cancer surgery regarding urological and sexual dysfunction:a systematic review and metaanalysis. Colorectal Dis 2015;17:375-81.
 
2) Fujita S, et al:Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212):results from a multicentre, randomised controlled, non-inferiority trial. Lancet Oncol 2012;13:616-21.
 
P.266 掲載の参考文献
Bonjer HJ, Deijen CL, Abis GA, Cuesta MA, van der Pas MH, de Lange-de Klerk ES, Lacy AM, Bemelman WA, Andersson J, Angenete E, Rosenberg J, Fuerst A, Haglind E;COLOR II Study Group. A randomized trial of laparoscopic versus open surgery for rectal cancer. N Engl J Med 2015;372:1324-32.
 
P.273 掲載の参考文献
1) Kapiteijn E, et al:Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer, For The Dutch Colorectal Cancer Group. N Engl J Med 2001;345:638-46.
 
2) Jayne DG, et al:Randomized trial of laparoscopic-assisted resection of colorectal carcinoma:3-year results of the UK MRC CLASICC trial. J Clin Oncol 2007;25:3061-8.
 
3) Jeong SY, et al:Open versus laparoscopic surgery for mid-rectal or lowrectal cancer after neoadjuvant chemoradiotherapy (COREAN trial):survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol 2014;15:767-74.
 
4) Stevenson AR, et al:Effect of laparoscopic-assisted resection vs open resection on pathological outcomes in rectal cancer:the ALaCaRT randomized clinical trial. JAMA 2015;314:1356-63.
 
5) Fleshman J, et al:Effect of laparoscopic-assisted resection vs open resection of stage II or III rectal cancer on pathologic outcomes:the ACOSOG Z6051 randomized clinical trial. JAMA 2015;314:1346-55.
 
6) Hida K, et al;Japan Society of Laparoscopic Colorectal Surgery:Open versus laparoscopic surgery for advanced low rectal cancer:A large, multicenter, propensity score matched cohort study in japan. Ann Surg 2018;268:318-24.
 
P.278 掲載の参考文献
Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H, Wittekind C, Beissbarth T, Rodel C. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer:results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012;30:1926-33.
PubMed
P.286 掲載の参考文献
1) van Gijn W, et al (Dutch Colorectal Cancer Group):Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer:12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011;12:575-82.
PubMed
2) Bosset JF, et al:Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355:1114-23.
PubMed
3) Gerad JP, et al:Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancer:Results of FFCD 9203. J Clin Oncol 2006;24:4620-5.
PubMed
4) Sebag-Montefiore D, et al:Preoperative radiotherapy versus selective postoperative chemotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016):A multicentre, randomized trial. Lancet 2009;373:811-20.
PubMed
P.291 掲載の参考文献
Stillwell AP, Buettner PG, Ho YH. Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone. World J Surg 2010;34:797-807.
PubMed
P.297 掲載の参考文献
1) Cummins ER, et al:Incurable colorectal carcinoma:the role of surgical palliation. Am Surg 2004;70:433-7.
PubMed
2) Seo GJ, et al:Intestinal complications after palliative treatment for asymptomatic patients with unresectable stage IV colorectal cancer. J Surg Oncol 2010;102:94-9.
PubMed
3) Lee WS, et al:The outcome after stent placement or surgery as the initial treatment for obstructive primary tumor in patients with stage IV colon cancer. Am J Surg 2012;203:715-9.
 

書評

最近チェックした商品履歴

Loading...